TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01297465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f®
Description: Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pergoveris®
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris®
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: 250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: 250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).
Study: NCT04412265

Intervention type: OTHER
Intervention: Relation between frailty and clinical outcomes in elderly patients with COVID-19.
Description: To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration.
Study: NCT00920517

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rDEN2/4delta30(ME) vaccine
Description: 10\^3 PFU dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rDEN2/4delta30(ME) vaccine
Description: 10\^3 PFU dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo for rDEN2/4delta30(ME) vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo for rDEN2/4delta30(ME) vaccine
Study: NCT03287336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
Study: NCT03891966

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Splint
Description: 50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Dressing
Description: 50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
Study: NCT01239875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine therapy
Description: Given intratumorally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine therapy
Description: Given intratumorally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Undergo cryoablation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly
Study: NCT03554083

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study: NCT01239875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-tumor fusion vaccine
Description: Given intradermally
Study: NCT02161822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 80mg qd for 5weeks
Study: NCT01845831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine 50%
Description: Glargine will be prescribed at 50% of daily hospital dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine 80%
Description: Glargine will be prescribed at 80% of daily hospital dose.
Study: NCT02817308

Intervention type: OTHER
Group type: OTHER
Intervention: samples of blood, saliva and urine
Description: Spot samples of Blood, urine and saliva

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: samples of blood, saliva and urine
Description: Spot samples of Blood, urine and saliva
Study: NCT01048177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bladder instillation with heparin/ lidocaine
Description: 9 bladder instillations in 6 weeks
Study: NCT00760097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct stimulation
Description: sessions of 20 minutes each
Study: NCT01848691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of carbon monoxide level in exhaled breath
Description: Measurement of end-tidal carbon monoxide concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of carbon monoxide level in exhaled breath
Description: Measurement of end-tidal carbon monoxide concentration
Study: NCT00067665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
Study: NCT02195583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1426 ppm)
Description: Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
Study: NCT04036201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: peribulbar block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: peribulbar block
Study: NCT02195583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1150 ppm)
Description: Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (250 ppm)
Description: Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1426 ppm) + zinc base A
Description: Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1426 ppm) + zinc base B
Description: Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride (0 ppm)
Description: Non-zinc, 0ppm fluoride in a silica gel base
Study: NCT00514111

Intervention type: DRUG
Intervention: pegylated-interferon, conventional-interferon, ribavirin
Description: Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
Study: NCT02285192

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-Fluorodeoxyglucose (18F-FDG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI imaging
Study: NCT03822143

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Use of ultrasound device to diagnosis anemia in a fetus
Study: NCT02924259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GRID foam roll
Description: Commercial rigid foam roll with an outer foam covering
Study: NCT02266147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT02748252

Intervention type: OTHER
Intervention: stroke center referral
Study: NCT02211937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 44847 solution, low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 44847 suspension, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847 tablet, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847 tablet, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847 tablet, high dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study: NCT02788812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open modified Lichtenstein repair
Description: Open Lichtenstein Hernioplasty
Study: NCT04388215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-828
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-828(placebo)
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D326
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D326(placebo)
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D337
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D337
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D337(placebo)
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D013
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D013(placebo)
Description: orally, 1 tablet once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013(placebo)
Description: orally, 1 tablet once a day for 8 weeks
Study: NCT04863053

Intervention type: OTHER
Intervention: Blood samples will be taken to assess platelet function. There is no change in treatment.
Study: NCT02788812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP inguinal hernia repair
Description: Laparoscopic TAPP Hernioplasty
Study: NCT02168101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg.
Study: NCT04498286

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing of SARS-CoV-2 antibodies
Description: Sars-CoV-2 RBD total antibody test developed by Sanquin
Study: NCT01435694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lokomat (Hocoma, Switzerland)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Study: NCT03953677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 100 Mcg/mL Intravenous Solution
Description: Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose Infusion solution
Description: Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
Study: NCT03689569

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Patients will be given 30 grams of corn starch
Study: NCT02363777

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral catheters
Description: Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
Study: NCT04404673

Intervention type: PROCEDURE
Intervention: Evaluation of urinary and sexual dysfunction after rectal resection
Description: Comparison among the 4 different surgical approaches for urinary and sexual function

Intervention type: PROCEDURE
Intervention: Evaluation of urinary and sexual dysfunction after rectal resection
Description: Comparison among the 4 different surgical approaches for urinary and sexual function

Intervention type: PROCEDURE
Intervention: Evaluation of urinary and sexual dysfunction after rectal resection
Description: Comparison among the 4 different surgical approaches for urinary and sexual function

Intervention type: PROCEDURE
Intervention: Evaluation of urinary and sexual dysfunction after rectal resection
Description: Comparison among the 4 different surgical approaches for urinary and sexual function
Study: NCT01845246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prospective TDM Arm of colistin
Study: NCT02872870

Intervention type: BEHAVIORAL
Intervention: auditory lexical decision task

Intervention type: BEHAVIORAL
Intervention: auditory lexical decision task

Intervention type: BEHAVIORAL
Intervention: auditory lexical decision task

Intervention type: DEVICE
Intervention: electroencephalogram

Intervention type: DEVICE
Intervention: electroencephalogram

Intervention type: DEVICE
Intervention: electroencephalogram
Study: NCT01403779

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity modulated radiotherapy (IMRT) for breast cancer
Description: right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity modulated radiotherapy (IMRT) for breast cancer
Description: right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
Study: NCT04859348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy
Description: G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine physical therapy and antenatal exercises
Description: G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
Study: NCT02676674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
Study: NCT03012191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
Study: NCT01773967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGG
Description: LGG 10\^10 cfu PO BID X 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: micro-crystalline cellulose
Description: 1 capsule PO bid x 5 days
Study: NCT04177615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboectomy
Description: Thromboectomy in Basilar Artery Occlusion patients
Study: NCT02226588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Study: NCT00847899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR9281
Description: AR9281 taken in BID dosing regimen for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR9281
Description: AR9281 taken in TID dosing regimen for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken in BID dosing regimen for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken in TID dosing regimen for 28 days
Study: NCT01109615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 400 mg/m2 on day 1 of a 3 weeks cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
Study: NCT03388801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).